Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors.
Siu LL, Pili R, Duran I, Messersmith WA, Chen EX, Sullivan R, MacLean M, King S, Brown S, Reid GK, Li Z, Kalita AM, Laille EJ, Besterman JM, Martell RE, Carducci MA.
Siu LL, et al. Among authors: messersmith wa.
J Clin Oncol. 2008 Apr 20;26(12):1940-7. doi: 10.1200/JCO.2007.14.5730.
J Clin Oncol. 2008.
PMID: 18421048
Free PMC article.
Clinical Trial.